Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

HCV (hepatitis C virus) core antigen and antibody thereof as well as hybridoma cell lines secreting antibody

A technology of hepatitis C virus and hybridoma cell lines, applied in the direction of viral peptides, antiviral immunoglobulins, analytical materials, etc., can solve the problems of difficult large-scale screening, complicated detection operations, expensive prices, etc., and achieve reliable Detection method, high purity, and high-efficiency secretion effect

Active Publication Date: 2012-01-25
SHANDONG UNIV QILU HOSPITAL
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows us to create small pieces (called fragments) that contain specific parts or structures within an organism's DNA called genome. These tiny particles may also include certain proteins like enzymes involved with viruses such as Hep Gamma Virus). They help scientists study how they infect cells more effectively than other methods currently available. By analyzing these smaller sections we aimed at developing new ways to detect this disease through molecular biology tools.

Problems solved by technology

This patent describes how treatments targeting various diseases like cancer have been developed but they may be complicated or costly due to their complexity and instabilities. Current testing protocols involve measuring levels of circulating proteins such as alpha fetus growth factor (AFG), beta-2 microglobulocyte stimulating hormones called cytokines, tumor necrosis mediator substances, cytology histochemistry analysis, etc., while developing effective therapies based upon these indicators could help improve outcomes from those who contract any form of hepatic failure during chemotherapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HCV (hepatitis C virus) core antigen and antibody thereof as well as hybridoma cell lines secreting antibody
  • HCV (hepatitis C virus) core antigen and antibody thereof as well as hybridoma cell lines secreting antibody
  • HCV (hepatitis C virus) core antigen and antibody thereof as well as hybridoma cell lines secreting antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] The preparation of embodiment one immunogen

[0031] 1. Design and synthesize the primer sequence of the HCV core region gene fragment (synthesized by Shanghai Boshang Biotechnology Co., Ltd.), as shown in SEQ ID NO.3 and 4.

[0032] 2. Extract HCV infected patients (20 HCV serum samples used for HCV RNA extraction are from HCV-RNA positive but HCV antibody-negative patients collected by Qilu Hospital of Shandong University, including 16 males and 4 females, with an average age of 45 years old. The genotyping test results were 13 cases of Ib subtype, 7 cases of 2a subtype) serum RNA, reverse transcription PCR, and the reaction system was as follows:

[0033]

[0034] The PCR reaction was carried out according to the following conditions: 94°C for 30s, 55°C for 30s, 72°C for 30s, after 35 cycles, 72°C for 10min.

[0035] 3. After agarose gel electrophoresis, the target PCR product was recovered from the gel, connected to the pMD18-T vector, and transformed into DH5α ...

Embodiment 2

[0046] Embodiment 2 hybridoma preparation monoclonal antibody

[0047] 1. Animal immunity:

[0048] Select 6-week-old Balb / c female mice, subcutaneously inject the immunogen at multiple points, use Freund's complete adjuvant, mix at a ratio of 1:1, and inject subcutaneously with incomplete Freund's adjuvant 10 days after the initial immunization, once a week, three times in a row. After the last immunization, blood was collected by docking the tail, and the mouse antibody titer was initially identified by indirect ELISA method. After 10 days, a booster immunization was given.

[0049] 2. Cell fusion:

[0050] Before fusion, mouse myeloma cells SP2 / 0 were resuscitated and cultured with 8-azaguanine to ensure that the cells were in the best growth state during fusion. On the day of fusion, mouse peritoneal macrophages were taken to prepare feeder cells, and 10ml HAT medium was added to seed them in 96-well plates.

[0051] Three days after the booster immunization of the im...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an HCV (hepatitis C virus) core antigen, which is a polypeptide encoded by a DNA (deoxyribonucleic acid) of which the amino acid sequence is shown in SEQ ID NO.1 and the nucleotide sequence is shown in SEQ ID NO.2. The invention also discloses a hybridoma cell line secreting monoclonal antibodies, the hybridoma cell line is named as SC16-H6 and has been preserved in the China General Microbiological Culture Collection Center on July 14th, 2011, and the preservation number is CGMCC No. 5074. The invention also discloses another hybridoma cell line secreting monoclonal antibodies, the hybridoma cell line is named as SC23-G5 and has been preserved in the China General Microbiological Culture Collection Center on July 14th, 2011, and the preservation number is CGMCC No. 5075. The invention also discloses a monoclonal antibody of an anti-HCV core antigen, which is secreted by the hybridoma cell line (preservation number: CGMCC No. 5074) or the hybridoma cell line (preservation number: CGMCC No. 5075), and has a specificity to the polypeptide shown in SEQ ID No.1.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner SHANDONG UNIV QILU HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com